World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
103
Citations
42970
World Ranking
7310
National Ranking
3828

Research.com Recognitions

  • 2012 - Fellow, National Academy of Inventors

Overview

Alan F. List is affiliated with Precision BioSciences in the United States and has contributed extensively to the field of medicine, particularly focusing on hematology, genetics, immunology, molecular biology, and oncology. Their research intersects multiple subfields, with a strong emphasis on blood disorders and cancer-related conditions.

The scientist's main research topics include:

  • Acute Myeloid Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Inflammasome and immune disorders
  • CAR-T cell therapy research
  • Neutropenia and Cancer Infections
  • Immune cells in cancer
  • Acute Lymphoblastic Leukemia research

Their frequent publication venues reflect a focus on hematologic and oncological research. These include:

  • Blood
  • Leukemia
  • Journal of Clinical Oncology
  • Blood Advances
  • Clinical Lymphoma Myeloma & Leukemia

Among recent papers, Alan F. List has been connected to several notable works, such as:

  • Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (2020), published in New England Journal of Medicine
  • Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes (2021), published in Journal of Clinical Oncology
  • TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype (2020), published in Blood
  • Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS (2020), published in Leukemia
  • Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes (2021), published in Blood Advances

Collaborative efforts with frequent co-authors include:

  • Eric Padron
  • Rami S. Komrokji
  • David A. Sallman
  • Mikkael A. Sekeres
  • Amy E. DeZern

Alan F. List was recognized as a Fellow of the National Academy of Inventors in 2012, reflecting a professional standing that intersects research and innovation. Their work spans over a hundred publications primarily focused on medical research, contributing significantly to the understanding and treatment of hematologic malignancies and associated immune disorders.

Best Publications

  • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

    Pierre Fenaux;Ghulam J. Mufti;Eva Hellstrom-Lindberg;Valeria Santini

  • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

    Alan List;Gordon Dewald;John Bennett;Aristotle Giagounidis

  • Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

    R H Collins;O Shpilberg;W R Drobyski;D L Porter

  • Efficacy of lenalidomide in myelodysplastic syndromes.

    Alan List;Sandy Kurtin;Denise J. Roe;Andrew Buresh

  • Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

    Pierre Fenaux;Ghulam J. Mufti;Eva Hellström-Lindberg;Valeria Santini

  • Epidemiology of Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders in the United States, 2001-2004, Using Data From the NAACCR and SEER Programs

    Dana E. Rollison;Nadia Howlader;Martyn T. Smith;Sara S. Strom

  • Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

    Azra Raza;James A. Reeves;Eric J. Feldman;Gordon W. Dewald

  • Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.

    Alan F. List;Kenneth J. Kopecky;Cheryl L. Willman;David R. Head

  • Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.

    Hagop Kantarjian;Susan O'Brien;Farhad Ravandi;Jorge Cortes

  • Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia

    C L Willman;C E Sever;M G Pallavicini;H Harada

  • Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

    William T. Bellamy;Lynne Richter;Davuud Sirjani;Concepcion Roxas

  • Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

    Pierre Fenaux;Pierre Fenaux;Uwe Platzbecker;Ghulam J. Mufti;Guillermo Garcia-Manero

  • STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia

    Andres Jerez;Michael J. Clemente;Hideki Makishima;Hanna Koskela

  • Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.

    A F List;C Spier;J Greer;S Wolff

  • First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

    Eric J. Feldman;Jeffrey E. Lancet;Jonathan E. Kolitz;Ellen K. Ritchie

  • Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A

    Anna M. Jankowska;Hideki Makishima;Ramon V. Tiu;Hadrian Szpurka

  • Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia

    Alan F. List;Catherine S. Spier;Thomas M. Grogan;Cynthia Johnson

  • Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.

    David A Sallman;Amy E DeZern;Guillermo Garcia-Manero;David P Steensma

  • The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

    Ashley A. Basiorka;Kathy L. McGraw;Erika A. Eksioglu;Xianghong Chen

  • The thalidomide saga.

    Magda Melchert;Alan List

Frequent Co-Authors

Mikkael A. Sekeres
Mikkael A. Sekeres Cleveland Clinic
Jaroslaw P. Maciejewski
Jaroslaw P. Maciejewski Cleveland Clinic
Pierre Fenaux
Pierre Fenaux Université Paris Cité
Ghulam J. Mufti
Ghulam J. Mufti King's College London
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Sheng Wei
Sheng Wei University of South Florida
David P. Steensma
David P. Steensma Harvard University
Eva Hellström-Lindberg
Eva Hellström-Lindberg Karolinska University Hospital
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Amit Verma
Amit Verma Albert Einstein College of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn't always require attending a traditional medical school. There are many flexible online options that can help you get started in the healthcare field or advance your current career. Exploring affordable online FNP programs is a great way to become a Family Nurse Practitioner, a highly respected and in-demand profession in the U.S.

For those who want to start in nursing, you can look into affordable nursing programs that allow you to study online at your own pace. If you are already a registered nurse and want to enhance your credentials, the cheapest RN to BSN program can help you open more career opportunities and increase your earning potential.

Interested in research or teaching at the highest levels? The cheapest PhD nursing programs online offer a cost-effective route to advanced expertise and leadership roles. All of these online pathways provide flexible, affordable alternatives for those looking to build a rewarding healthcare career in the USA.

Best Scientists Citing Alan F. List

Trending Scientists